Source comparison
Thymosin Alpha-1 vs Other Immunomodulatory Peptides in Cancer Research
Thymosin Alpha-1 TLR2 agonist → dendritic cell maturation → IL-2 / IFN-γ upregulation CD4+ and CD8+ T-cell counts increase 30–50% by week 4 Phase III (HCC, NSCLC) Adjunct to chemotherapy in solid tumors; immune recovery post-myelosuppression Thymalin Thymic pe
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- TLR2 agonist → dendritic cell maturation → IL-2 / IFN-γ upregulation
- CD4+ and CD8+ T-cell counts increase 30–50% by week 4
- Phase III (HCC, NSCLC)
- Adjunct to chemotherapy in solid tumors; immune recovery post-myelosuppression
- Thymalin
- Thymic peptide extract → broad thymopoiesis stimulation
- Mixed—promotes regulatory T-cell expansion alongside effector cells
- Phase II (limited)
- Autoimmune model studies; not cancer-specific
- LL-37 (Cathelicidin)
- Antimicrobial peptide → neutrophil activation
- Primarily innate immunity; minimal adaptive T-cell effect
- Preclinical
- Infection prophylaxis in immunocompromised patients; not adjunct oncology
- Epithalon
- Telomerase modulator → theoretical anti-senescence
- No validated immune function data in humans
- Speculative / unproven
- Aging research; lacks oncology evidence base